S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
Is This The End of Capitalism? (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
Is This The End of Capitalism? (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
Is This The End of Capitalism? (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
FTX's Sam Bankman-Fried, DOJ tussle over his communications
Is This The End of Capitalism? (Ad)
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
Qatar replaces Russian company in Lebanon gas exploration
NASDAQ:SLRX

Salarius Pharmaceuticals - SLRX Short Interest Ratio & Short Volume

$2.42
-0.14 (-5.47%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.35
$2.76
50-Day Range
$1.13
$3.58
52-Week Range
$1.07
$13.46
Volume
285,640 shs
Average Volume
474,427 shs
Market Capitalization
$5.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$100.00

Salarius Pharmaceuticals Short Interest Data

Current Short Volume
73,400 shares
Previous Short Volume
19,700 shares
Change Vs. Previous Month
+272.59%
Dollar Volume Sold Short
$194,510.00
Short Interest Ratio / Days to Cover
0.4
Last Record Date
January 15, 2023
Outstanding Shares
2,280,000 shares
Float Size
1,950,000 shares
Short Percent of Float
3.76%
Today's Trading Volume
285,640 shares
Average Trading Volume
474,427 shares
Today's Volume Vs. Average
-39.79%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Salarius Pharmaceuticals ?

Sign up to receive the latest short interest report for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

SLRX Short Interest Over Time

SLRX Days to Cover Over Time

SLRX Percentage of Float Shorted Over Time


Salarius Pharmaceuticals (NASDAQ:SLRX) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/15/202373,400 shares $194,510.00 +272.6%3.8%0.4 $2.65
12/30/202219,700 shares $30,141.00 -46.6%1.0%0.3 $1.53
12/15/202236,900 shares $55,719.00 +93.2%1.9%0.8 $1.51
11/30/202219,100 shares $36,863.00 -12.0%1.0%0.4 $1.93
11/15/202221,700 shares $46,655.00 +100.9%1.1%0.5 $2.15
10/31/202210,800 shares $21,924.00 -31.2%0.5%0.3 $2.03
10/15/202215,700 shares $71,042.50 -95.8%0.8%0.4 $4.53
9/30/2022371,000 shares $72,345.00 -8.4%N/A0.9 $0.20
9/15/2022405,000 shares $95,904.00 +9.6%N/A0.8 $0.24
8/31/2022369,500 shares $74,269.50 -16.3%N/A0.7 $0.20
8/15/2022441,600 shares $99,360.00 +257.3%N/A0.7 $0.23
7/31/2022123,600 shares $23,508.72 +7.3%N/A0.1 $0.19
7/15/2022115,200 shares $21,876.48 -33.8%N/A0.1 $0.19
6/30/2022174,100 shares $36,561.00 -54.6%N/A0.1 $0.21
6/15/2022383,300 shares $77,733.24 -9.8%N/A0.3 $0.20
5/31/2022425,000 shares $76,627.50 -3.8%N/A0.4 $0.18
5/15/2022441,800 shares $83,014.22 -26.6%N/A0.4 $0.19
4/30/2022602,200 shares $121,644.40 +31.4%N/A1.1 $0.20
4/15/2022458,300 shares $163,658.93 -14.7%N/A1.1 $0.36
3/31/2022537,100 shares $213,819.51 +11.7%N/A1.3 $0.40
3/15/2022480,900 shares $165,429.60 -23.8%N/A1 $0.34
2/28/2022630,900 shares $252,423.09 +0.4%N/A1.8 $0.40
2/15/2022628,200 shares $285,831.00 -3.7%N/A1.7 $0.46
1/31/2022652,400 shares $293,580.00 -2.0%4.5%1.5 $0.45
1/15/2022665,600 shares $312,832.00 +4.2%4.6%1.4 $0.47
12/31/2021638,500 shares $316,440.60 -7.3%4.4%1.3 $0.50
12/15/2021688,600 shares $365,853.18 -35.0%4.7%1.4 $0.53
11/30/20211,060,000 shares $689,000.00 +1.0%7.3%1.5 $0.65
11/15/20211,050,000 shares $796,950.00 +7.5%7.2%1.1 $0.76
10/29/2021976,600 shares $808,331.82 -0.2%6.7%0.8 $0.83
10/15/2021978,900 shares $886,002.39 -24.1%6.7%0.8 $0.91
9/30/20211,290,000 shares $1.32 million -4.4%8.9%1 $1.02
9/15/20211,350,000 shares $1.39 million -2.9%9.3%1 $1.03
8/31/20211,390,000 shares $1.45 million +9.5%9.6%1 $1.04
8/13/20211,270,000 shares $1.17 million -8.0%8.8%0.7 $0.92
7/30/20211,380,000 shares $1.12 million -9.2%9.5%0.8 $0.81
7/15/20211,520,000 shares $1.38 million -19.2%10.5%0.9 $0.91
6/30/20211,880,000 shares $1.99 million +0.5%13.0%1.1 $1.06
6/15/20211,870,000 shares $2.24 million +14.7%12.9%1.1 $1.20
5/28/20211,630,000 shares $2.09 million -2.4%11.3%1 $1.28













SLRX Short Interest - Frequently Asked Questions

What is Salarius Pharmaceuticals' current short interest?

Short interest is the volume of Salarius Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of January 15th, investors have sold 73,400 shares of SLRX short. 3.76% of Salarius Pharmaceuticals' shares are currently sold short. Learn More on Salarius Pharmaceuticals' current short interest.

What is a good short interest percentage for Salarius Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.76% of Salarius Pharmaceuticals' floating shares are currently sold short.

Is Salarius Pharmaceuticals' short interest increasing or decreasing?

Salarius Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 73,400 shares, an increase of 272.6% from the previous total of 19,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Salarius Pharmaceuticals' float size?

Salarius Pharmaceuticals currently has issued a total of 2,280,000 shares. Some of Salarius Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Salarius Pharmaceuticals currently has a public float of 1,950,000 shares.

How does Salarius Pharmaceuticals' short interest compare to its competitors?

3.76% of Salarius Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Salarius Pharmaceuticals: Petros Pharmaceuticals, Inc. (2.36%), NeuroBo Pharmaceuticals, Inc. (15.29%), Enveric Biosciences, Inc. (2.04%), PainReform Ltd. (0.26%), OncoSec Medical Incorporated (3.20%), Tricida, Inc. (21.79%), Sonoma Pharmaceuticals, Inc. (1.65%), Qualigen Therapeutics, Inc. (2.50%), Ensysce Biosciences, Inc. (1.73%), and Aditxt, Inc. (1.25%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.43 billion), T. Rowe Price Group, Inc. ($2.26 billion), Coinbase Global, Inc. ($2.19 billion), Etsy, Inc. ($1.78 billion), Paramount Global ($1.77 billion), Old Dominion Freight Line, Inc. ($1.69 billion), United Rentals, Inc. ($1.53 billion), American Airlines Group Inc. ($1.52 billion), PG&E Co. ($1.48 billion), and Voya Financial, Inc. ($1.47 billion). View all of the most shorted stocks.

What does it mean to sell short Salarius Pharmaceuticals stock?

Short selling SLRX is an investing strategy that aims to generate trading profit from Salarius Pharmaceuticals as its price is falling. SLRX shares are trading down $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Salarius Pharmaceuticals?

A short squeeze for Salarius Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SLRX, which in turn drives the price of the stock up even further.

How often is Salarius Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SLRX, twice per month. The most recent reporting period available is January, 15 2023.



This page (NASDAQ:SLRX) was last updated on 1/29/2023 by MarketBeat.com Staff